CERo Therapeutics Hldgs 주식 (NASDAQ: CERO)

에 대한 최신 뉴스 CERo Therapeutics Hldgs (NASDAQ:CERO) 주식

CERo Therapeutics Hldgs

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Holdings Inc

CERo Therapeutics Holdings, Inc. - Warrants

CERO THERAPEUTICS HOLDINGS INC UNIT 1 CL A & 1/3 WT EXP

Evercore ISI Group analyst Jonathan Chappell maintains Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) with a Outperform and lowers the price target from $415 to $298.

News

Price Target

Analyst Ratings

SAIA

Evercore ISI Group Maintains Outperform on Saia, Lowers Price Target to $298

<a href="https://www.bloomberg.com/news/articles/2025-04-28/sony-is-said-to-mull-chip-spinoff-that-loeb-called-for-years-ago" title="https://www.bloomberg.com/news/articles/2025-04-28/sony-is-said-to-mull-chip-spinoff-that-loeb-called-for-years-ago">https://www.bloomberg.com/news/articles/2025-04-28/sony-is-said-to-mull-chip-spinoff-that-loeb-called-for-years-ago</a>

Sony Group Corporation American Depositary Shares

SONY

'Sony Weighs Chip Spinoff That Dan Loeb Called for Years Ago' - Bloomberg News

Evercore ISI Group analyst Duane Pfennigwerth maintains Ryman Hospitality Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHP#NYSE">RHP</a>) with a Outperform and lowers the price target from $130 to $120.

Evercore ISI Group Maintains Outperform on Ryman Hospitality Props, Lowers Price Target to $120

Evercore ISI Group analyst Amit Daryanani maintains Pure Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>) with a Outperform and lowers the price target from $75 to $60.

PSTG

Evercore ISI Group Maintains Outperform on Pure Storage, Lowers Price Target to $60

JMP Securities analyst Constantine Davides reiterates Privia Health Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRVA#NASDAQ">PRVA</a>) with a Market Outperform and maintains $29 price target.

Reiteration

PRVA

JMP Securities Reiterates Market Outperform on Privia Health Gr, Maintains $29 Price Target

WIIM

ADMA

ADMA Biologics shares are trading higher after the company announced FDA approval of its yield enhancement production process.

JMP Securities analyst Constantine Davides reiterates Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Market Outperform and maintains $13 price target.

JMP Securities Reiterates Market Outperform on Evolent Health, Maintains $13 Price Target

Evercore ISI Group analyst Michael Lonegan maintains Portland Gen Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>) with a Outperform and lowers the price target from $51 to $48.

Evercore ISI Group Maintains Outperform on Portland Gen Electric, Lowers Price Target to $48

Evercore ISI Group analyst Richard Hightower maintains Park Hotels &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PK#NYSE">PK</a>) with a Outperform and lowers the price target from $16 to $13.

Evercore ISI Group Maintains Outperform on Park Hotels & Resorts, Lowers Price Target to $13

Evercore ISI Group analyst Richard Hightower maintains Pebblebrook Hotel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEB#NYSE">PEB</a>) with a In-Line and lowers the price target from $15 to $11.

Evercore ISI Group Maintains In-Line on Pebblebrook Hotel, Lowers Price Target to $11

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) with a Buy and maintains $30 price target.

IBRX

D. Boral Capital Maintains Buy on ImmunityBio, Maintains $30 Price Target

JMP Securities analyst Silvan Tuerkcan reiterates Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) with a Market Outperform and maintains $5 price target.

TSHA

JMP Securities Reiterates Market Outperform on Taysha Gene Therapies, Maintains $5 Price Target

International Business Machines Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) disclosed a $150 billion investment plan in the U.S. <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n45037154/ibm-unveils-150-billion-investment-in-america-to-accelerate-technology-opportunity" rel="noreferrer noopener">over the next five years</a>.
The initiative aims to drive economic growth and strengthen its position as a global computing leader.
In particular, the company plans to allocate over $30 billion toward research and development, focusing on advancing and expanding its American manufacturing of mainframe and quantum computers.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44987653/ibms-shares-drop-sharply-after-q1-report-analysts-say-its-overdone-revenue-growth-to-accelerate" rel="noreferrer noopener">IBM&#8217;s Shares Drop Sharply After Q1 Report: Analysts Say It&#8217;s Overdone, Revenue Growth To Accelerate</a>
Arvind Krishna, IBM chairman, president and CEO said, &#8220;We have been focused on American jobs and manufacturing since our founding 114 years ago, and with this investment and manufacturing commitment we are ensuring that IBM remains the epicenter of the world&#8217;s most advanced computing and AI capabilities.&#8221; 
In addition, the company unveiled new agentic and automation features in its managed detection and response services to enhance autonomous security operations and provide <a href="https://www.benzinga.com/pressreleases/25/04/n45037811/ibm-delivers-autonomous-security-operations-with-cutting-edge-agentic-ai" target="_blank" rel="noreferrer noopener">predictive threat intelligence for clients</a>.
In particular, the company is introducing the Autonomous Threat Operations Machine (ATOM), an agentic AI system designed to autonomously handle threat triage, investigation, and remediation with minimal human input.
IBM is also launching the X-Force Predictive Threat Intelligence (PTI) agent for ATOM, which uses industry-specific AI foundation models to deliver predictive insights on potential adversarial activities and reduce the need for manual threat hunting.
This month, IBM reported first-quarter earnings of $1.60 per share, which exceeded the analyst consensus estimate of $1.40 and revenue of $14.54 billion, also surpassing the analyst<a href="https://www.benzinga.com/news/earnings/25/04/44966124/ibm-shares-slide-despite-better-than-expected-q1-details" target="_blank" rel="noopener"> consensus estimate of $ 14.40</a><a href="https://www.benzinga.com/news/earnings/25/04/44966124/ibm-shares-slide-despite-better-than-expected-q1-details" target="_blank" rel="noreferrer noopener"> billion</a>.
Investors can gain exposure to the stock via&nbsp;First Trust NASDAQ Technology Dividend Index Fund&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDIV#NASDAQ">TDIV</a>) and FT Vest Technology Dividend Target Income ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/TDVI#BATS">TDVI</a>).
Price Action: IBM shares are up 0.16% at $232.79 premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/04/45027471/consumer-tech-news-apr-21-apr-25-microsofts-copilot-gets-a-sleek-new-look-apple-under-fire-for-influence-peddling-in-us-china-trade-more" target="_blank" rel="noreferrer noopener">Consumer Tech News (Apr 21-Apr 25): Microsoft&#8217;s Copilot Gets a Sleek New Look, Apple Under Fire For &#8216;Influence-Peddling&#8217; In US-China Trade &amp; More</a></li>
</ul>
Photo: Shutterstock

Equities

Large Cap

Movers

TDIV

TDVI

IBM Commits $30 Billion To R&D In US, Eyes Next-Level Advances In Mainframes And Quantum Computing

Progressive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) has outperformed the market over the past 10 years by 15.62% on an annualized basis producing an average annual return of 25.8%. Currently, Progressive has a market capitalization of $158.28 billion. 
Buying $1000 In PGR: If an investor had bought $1000 of PGR stock 10 years ago, it would be worth $9,906.23 today based on a price of $270.00 for PGR at the time of writing.
<h3>Progressive's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745851520_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In Progressive 10 Years Ago Would Be Worth This Much Today

INMD

InMode shares are trading lower after the company reported worse-than-expected Q1 financial results and cut its FY25 adjusted EPS below estimates.

Evercore ISI Group analyst Michael Lonegan maintains PG&amp;E (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>) with a In-Line and raises the price target from $15 to $17.

Evercore ISI Group Maintains In-Line on PG&E, Raises Price Target to $17

BHVN

Biohaven shares are trading higher after the company announced a $600 million non-dilutive funding agreement with Oberland Capital to advance its rare disease portfolio.

D. Boral Capital analyst Jason Kolbert maintains Artelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) with a Buy and maintains $6 price target.

ARTL

D. Boral Capital Maintains Buy on Artelo Biosciences, Maintains $6 Price Target

PTON

Peloton shares are trading higher after Truist Securities upgraded the stock from Hold to Buy.

JMP Securities analyst Reni Benjamin reiterates Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) with a Market Outperform and maintains $40 price target.

SMMT

JMP Securities Reiterates Market Outperform on Summit Therapeutics, Maintains $40 Price Target

Press Releases

CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays

CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting

CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services

CERo Therapeutics Holdings, Inc.  Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing

CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors

CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company's Lead Compound CER-1236

Contracts

CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing

CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

Comments

CERo Therapeutics Hldgs

뉴스

에 대한 최신 뉴스 CERo Therapeutics Hldgs (NASDAQ:CERO) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌